Cancer Council Victoria | Victorian Cancer Trials Link

A Phase 1b/2, Open-Label, Dose-Finding Study To Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab (MSB0010718C) In Combination With Either Crizotinib Or PF-06463922 In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer

Clinical summary

The purpose of this study is to evaluate the safety and efficacy of avelumab when combined with either crizotinib or PF-06463922.

Conditions

This trial is treating patients with Non-Small Cell (NSC) Lung Cancer

Trial Acronym
Javelin Lung 101

Trial Identifiers
NCT02584634
B9991005, 2015-001879-43, CT781

Cancer
Lung, Non-Small Cell Lung Cancer

Age: 18 to 75
Phase: I/II

For full trial details, visit trials.cancervic.org.au/details/vctl_nct02584634